Literature DB >> 6124232

Genetic regulation of neurotransmitter enzymes and receptors: relationship to the inheritance of psychiatric disorders.

R D Ciaranello, R E Boehme.   

Abstract

This report begins with a summary of the evidence for genetic involvement in certain major psychiatric syndromes. The relation of these disorders to deficits in central nervous system neurotransmitters is also summarized. These reviews serve as an introduction to our studies on the genetic regulation of neurotransmitters and their enzymes and receptors in inbred mice. The steady-state levels of the adrenal catecholamine biosynthetic enzymes are controlled genetically; not only is each enzyme regulated by a single locus, but also there is statistical evidence that the phenotypic expression of the entire pathway is regulated by a single gene. Studies on the biochemical mechanism of gene action suggest that genetic regulation is exerted on proteolysis of the enzymes, rather than their synthesis. In addition, we have examined the genetic control of dopamine receptors in inbred mice. Dopaminergic receptors in the nigrostriatal and mesolimbic pathways are under genetic control. Preliminary evidence suggests that the pathways are regulated by different genetic systems. If this early speculation proves true, it would have important clinical implications.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124232     DOI: 10.1007/bf01065738

Source DB:  PubMed          Journal:  Behav Genet        ISSN: 0001-8244            Impact factor:   2.805


  54 in total

1.  Mental illness in the biological and adoptive families of adopted individuals who have become schizophrenic: a preliminary report based on psychiatric interviews.

Authors:  S S Kety; D Rosenthal; P H Wender; F Schulsinger; B Jacobsen
Journal:  Proc Annu Meet Am Psychopathol Assoc       Date:  1975

2.  On the significance of the increase in homovanillic acid (HVA) caused by antipsychotic drugs in corpus striatum and limbic forebrain.

Authors:  R J Stawarz; H Hill; S E Robinson; P Setler; J V Dingell; F Sulser
Journal:  Psychopharmacologia       Date:  1975-08-21

3.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

4.  Effects of neuroleptics on 3H-haloperidol and 3H-cis(Z)-flupenthixol binding and on adenylate cyclase activity in vitro.

Authors:  J Hyttel
Journal:  Life Sci       Date:  1978-08-14       Impact factor: 5.037

5.  Genetic variation in activity of enzymes involved in synthesis of catecholamines.

Authors:  S Kessler; R D Ciaranello; J G Shire; J D Barchas
Journal:  Proc Natl Acad Sci U S A       Date:  1972-09       Impact factor: 11.205

Review 6.  The catecholamine hypothesis of affective disorders: a review of supporting evidence.

Authors:  J J Schildkraut
Journal:  Am J Psychiatry       Date:  1965-11       Impact factor: 18.112

7.  Catecholamines: strain differences in biosynthetic enzyme activity in mice.

Authors:  R D Ciaranello; R Barchas; S Kessler; J D Barchas
Journal:  Life Sci I       Date:  1972-06-15

8.  Antipsychotic drugs and catecholamine synapses. Summary of the session.

Authors:  N E Andén
Journal:  J Psychiatr Res       Date:  1974       Impact factor: 4.791

9.  Regulation of dopamine beta-hydroxylase synthesis and degradation ascorbic acid stabilization of the enzyme against tryptic proteolysis.

Authors:  D L Wong; S J Masover; R D Ciaranello
Journal:  J Biol Chem       Date:  1981-01-25       Impact factor: 5.157

10.  Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol.

Authors:  S J Peroutka; S H Snyder
Journal:  Mol Pharmacol       Date:  1979-11       Impact factor: 4.436

View more
  1 in total

1.  L-Tyrosine-3-hydroxylase regulation in the brain: genetic aspects.

Authors:  C Vadasz; G Kobor; A Lajtha; I Sziraki; A Fleischer
Journal:  Amino Acids       Date:  1992-10       Impact factor: 3.520

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.